Vetrov & Partners acted for a foreign pharmaceutical company on trademark registration strategy in Russia, including Rospatent proceedings and EAEU considerations. Make an enquiry.
Acted for foreign client in trademark registration strategy in Russia in the pharmaceuticals sector — IP matter — Russia, France
Client. A French pharmaceutical company holding a portfolio of proprietary medicinal trademarks sought to establish and defend its brand registrations across the Russian market, including coverage of product classes with regulatory significance under Russian pharmaceutical licensing rules.
Background. The client's existing registration position in Russia did not fully reflect the scope of its commercial activity, leaving certain product classes and transliterated brand variants exposed. A third-party applicant had filed competing applications at Rospatent for designations closely resembling the client's principal marks, creating a risk of conflicting registrations that would have undermined the client's ability to enforce exclusivity and obtain the regulatory approvals required for pharmaceutical market authorisation in Russia. The matter required coordinated action across Rospatent administrative proceedings and an assessment of EAEU-wide registration strategy, given the client's parallel distribution activity in CIS member states.
Our role. Counsel conducted a full audit of the client's existing Russian and EAEU trademark portfolio, identified gaps across relevant pharmaceutical product classes, and filed priority applications at Rospatent to establish the client's position ahead of the competing applicant. Counsel prepared and submitted opposition materials in the Rospatent administrative review process, including substantive observations on the likelihood of confusion and the client's prior use in the Russian market. Counsel also advised on the interaction between Russian trademark registration and the pharmaceutical regulatory approval process under Russian licensing requirements.
Outcome. Criminal charges not brought; investigation closed. The Rospatent proceedings resulted in the competing applications being refused, and the client's priority applications proceeded to registration without substantive objection. The client's trademark position across the relevant pharmaceutical product classes was secured, enabling continuation of its regulatory approval and distribution arrangements in Russia.
Discuss a similar matter — info@vetrovpartners.com
This briefing is general information and does not constitute legal advice. For advice on a specific matter, write in confidence to info@vetrovpartners.com.
Our team advises foreign clients on exactly these questions across Russia and the EAEU region. Initial 30-minute consultation — complimentary.
Make an enquiry